The finding is significant because keratins have long been treated mainly as identity markers rather than functional players. Intermediate filament proteins such as keratins form part of the cytoskeletal scaffold that gives epithelial cells their shape and resilience. Yet over the past two decades, evidence has accumulated that certain keratins, particularly those normally absent from a given tissue but induced under stress—so-called stress keratins—do far more than provide mechanical support. KRT17, a type I intermediate filament, has been implicated in tumor progression in several other cancers, promoting proliferation, survival under metabolic stress, and motility. Whether it played a comparable role in endometrial cancer, however, had remained an open question.

To answer it, the research team led by Xiaole Song, Xuerou Chen, and corresponding author Fang Ren combined large-scale bioinformatics with laboratory experiments at single-cell resolution. Mining data from The Cancer Genome Atlas for uterine corpus endometrial carcinoma, the researchers found that KRT17 expression was significantly elevated in endometrial cancer tissues compared with healthy endometrium. Crucially, the elevation was not merely a molecular curiosity. Patients whose tumors expressed high levels of KRT17 showed reduced overall survival and adverse clinical outcomes, establishing the protein as a marker of aggressive disease and a potential prognostic indicator that could eventually complement existing clinical classification.

But tissue-level averages can be deceiving. A bulk tumor sample contains a mixture of malignant epithelial cells, immune cells, fibroblasts, endothelial cells, and other stromal components, and gene signatures measured across such a mixture may reflect shifts in cellular composition rather than changes within the cancer cells themselves. To disentangle this, the team turned to single-cell RNA sequencing, a technique that captures the transcriptomes of individual cells and allows researchers to pinpoint exactly which cell types are expressing a given gene. The scRNA-seq analysis revealed that KRT17 was concentrated in the malignant epithelial cells of endometrial tumors, not in the surrounding microenvironment, confirming that the signal emanated from the cancer cells proper.

With the cellular source identified, the researchers then asked what KRT17-expressing tumor cells were actually doing. Differential expression analysis compared the gene expression profiles of KRT17-high and KRT17-low malignant cells, and pathway enrichment analyses were applied to the results to identify the biological programs associated with high KRT17. The answer pointed unambiguously to one process: epithelial-mesenchymal transition, or EMT. In EMT, epithelial cells—which are normally tightly packed, polarized, and anchored to their neighbors—shed their identity and acquire mesenchymal characteristics, becoming motile, invasive, and resistant to cell death. This transition is a well-established mechanism by which carcinomas invade surrounding tissue, enter blood and lymphatic vessels, and seed metastases at distant sites. The significant enrichment of KRT17 in the EMT pathway suggested that the keratin was not a passive bystander in this process but an active participant.

To test that hypothesis directly, the team performed loss-of-function experiments in endometrial cancer cells in the laboratory. Using stable knockdown to suppress KRT17 expression, they measured the effects on the core malignant behaviors of the cells. The results were consistent across multiple assays: cells lacking KRT17 proliferated more slowly, migrated less efficiently across wound and transwell-style assays, and showed a markedly reduced capacity to invade through extracellular-matrix-like barriers. The researchers also assessed spheroid formation—the ability of cells to grow into three-dimensional clusters that mimic tumor architecture—and found this too was significantly impaired without KRT17. In parallel, the knockdown altered the expression of key EMT markers, the molecular signposts that distinguish epithelial from mesenchymal states, indicating that removing KRT17 pushed the cells back toward a less invasive, more epithelial phenotype.

The in vitro findings set the stage for the decisive test: does KRT17 matter in a living organism? Using animal models of endometrial cancer, the researchers showed that tumors engineered with KRT17 knockdown grew substantially less than control tumors. Moreover, analysis of the tumor tissue demonstrated that suppressing KRT17 reversed the EMT process in vivo, shifting the balance of EMT marker expression back toward the epithelial state. Taken together with the cell culture data, the results establish KRT17 as a functional driver of endometrial cancer progression rather than a mere correlate—its presence enables the proliferation, migration, and invasion that make this disease deadly in its advanced stages.

The mechanistic picture that emerges is one in which KRT17 sits at the intersection of structural biology and signaling. The study’s pathway analyses connect KRT17 expression to a broader network of cancer-related pathways, including signaling cascades such as AKT/mTOR, which regulates cell growth and metabolism, and HIF-1α signaling, which governs the cellular response to low oxygen—a hallmark of the tumor microenvironment. Other genes tied to aggressive behavior, including MCL1, which promotes cell survival, and VEGF, which drives blood vessel formation, feature in the landscape of KRT17-associated biology. The single-cell and bulk tumor data also situate KRT17 within the molecular classification of endometrial cancer, which includes microsatellite instability-high, mismatch repair-deficient, and no specific molecular profile categories—context that will matter for determining which patient groups stand to benefit most from KRT17-directed approaches.

The clinical implications are twofold. First, as a biomarker, KRT17 could help stratify patients at diagnosis, flagging tumors likely to behave aggressively and guiding the intensity of surveillance and adjuvant treatment. The correlation between high KRT17 and reduced overall and disease-specific survival suggests it could be measured by established pathology techniques such as immunohistochemistry, which is already routine in clinical laboratories. Second, and more ambitiously, KRT17 represents a potential therapeutic target. The knockdown experiments demonstrate that reducing KRT17 levels cripples the malignant phenotype across the board—in proliferation, migration, invasion, and tumor-forming capacity. Translating that into a drug is no trivial matter, since targeting a cytoskeletal protein expressed in some normal tissues carries risks, but the study provides the proof of principle that interfering with KRT17 biology can blunt tumor progression and reverse EMT.

The researchers also emphasize the methodological significance of their approach. By integrating single-cell transcriptomics with bulk-level bioinformatics and classical wet-lab validation, the study exemplifies the modern pipeline for target discovery: computational screens generate hypotheses at population scale, single-cell data assign those hypotheses to specific cell types, and functional assays verify causation. This tiered strategy is increasingly seen as essential in cancer research, where bulk analyses alone frequently misattribute signals to the wrong cells. The fact that the KRT17-EMT link held up at every level—from patient survival data through single-cell expression profiles to animal models—lends the finding unusual robustness.

Much work remains before these results reach the clinic. The precise molecular mechanisms by which KRT17 activates or maintains EMT in endometrial cancer cells—whether through direct interactions with signaling proteins, effects on cell mechanics and adhesion, or regulation of transcriptional programs—will need to be worked out in detail. Prospective studies will be required to validate KRT17 as an independent prognostic marker across the diverse molecular subtypes of the disease, and any therapeutic development will need to address the question of specificity. Nevertheless, the study adds a compelling new name to the roster of molecules implicated in endometrial cancer progression, and it does so at a time when new targets for advanced and recurrent disease are urgently needed. For a cancer whose incidence continues to climb and whose treatment options narrow sharply once it spreads, every well-validated vulnerability matters—and Keratin 17, the humble structural filament turned aggressive driver, may prove to be one of the most actionable yet.

Endometrial cancer is a significant health concern, notably among women worldwide, with rising incidence rates. As research continues to unearth the molecular mechanisms driving cancer progression, the identification of key regulatory proteins, such as FABP7, becomes paramount. This study posits FABP7 as a crucial player in endometrial cancer cell behavior, thus providing pivotal insights that can potentially reshape treatment strategies.

FABP7 functions primarily as a transport protein within the cytoplasm, facilitating the transport of long-chain fatty acids. However, emerging evidence suggests that its role transcends mere lipid metabolism. The researchers demonstrated that FABP7 significantly enhances endometrial cancer cell migration and stemness—two critical characteristics associated with tumor metastasis and recurrence. This dual functionality indicates a shift in our understanding of FABP7, positioning it as a potential marker and therapeutic target in endometrial cancer.

One of the most compelling aspects of this research is the activation of the Wnt/β-catenin pathway by FABP7. The Wnt signaling cascade is known for its pivotal role in cell proliferation and differentiation in various cancers. This study demonstrates that FABP7 is not merely associated with the Wnt pathway; it actively participates in its activation, further linking metabolic dysregulation to oncogenic processes. The activation of β-catenin in the nucleus underscores a critical mechanism through which FABP7 enhances cancer cell traits, including increased migratory potential and stemness attributes.

Through a series of in vitro experiments, the researchers elucidated the precise mechanisms by which FABP7 modulates endometrial cancer cell behavior. Overexpression of FABP7 notably increased cell migration in various endometrial cancer cell lines, confirming its role as a pro-migratory factor. In contrast, silencing FABP7 expression resulted in the inhibition of cell migration, thereby supporting the hypothesis that FABP7 is integral to the metastatic capability of these cancer cells.

Another pivotal finding emerged surrounding the stemness properties of cancer cells. Cancer stem cells are recognized as a population within tumors that contribute to therapeutic resistance and tumor recurrence. The study found that FABP7 overexpression correlated with an increase in stem cell markers, suggesting that FABP7 may be influencing the stem cell-like characteristics within endometrial tumor cells. This observation adds a new layer of complexity to the role of FABP7 in cancer biology, as it intertwines metabolic factors with stem cell dynamics.

The implications of these findings extend to potential therapeutic strategies. Targeting the FABP7-Wnt/β-catenin axis may offer a novel approach for overcoming endometrial cancer treatment resistance. As the field of cancer therapy shifts towards precision medicine, identifying specific molecular targets such as FABP7 could enhance treatment efficacy and reduce side effects associated with conventional therapies. This study not only illuminates the underlying mechanisms of endometrial cancer progression but also sets the stage for innovative therapeutic interventions.

Furthermore, the research emphasizes the necessity of further investigations into how FABP7 interacts with other signaling pathways. The multifaceted role of FABP7 in cellular processes suggests that it may contribute to a broader network of regulatory mechanisms in cancer biology. Understanding these interactions is essential for developing comprehensive therapeutic strategies that target multiple facets of tumor behavior.

Additionally, consideration of the tumor microenvironment is crucial when examining the implications of FABP7 in endometrial cancer. The interaction between cancer cells and surrounding stromal cells, as well as immune cells, can significantly influence tumor behavior and response to therapies. Future studies should aim to explore how FABP7 contributes to these interactions and to what extent its activity is modulated by external stimuli within the tumor microenvironment.

In conclusion, the study by Xu et al. represents a significant advancement in our understanding of the molecular mechanisms underpinning endometrial cancer. By elucidating the role of FABP7 in augmenting cancer cell migration and stemness via the Wnt/β-catenin pathway, the researchers provide crucial insights that could inform future therapeutic approaches. The potential to target FABP7 not only opens doors to new treatment modalities but also underscores the importance of dissecting the complex cellular communications that characterize cancer progression. As we move forward, the research community must capitalize on these findings to develop targeted interventions that could transformative outcomes for patients with endometrial cancer.

In this era of rapid scientific advancement, the exploration of previously unrecognized roles of metabolic proteins like FABP7 may lead to significant breakthroughs in the personalized treatment of cancer. Continued research in this direction promises to enrich our understanding of cancer biology, ultimately translating into improved clinical outcomes.

Subject of Research: FABP7’s role in endometrial cancer progression through Wnt/β-catenin pathway activation.

Article Title: FABP7 Enhances Endometrial Cancer Cell Migration and Stemness by Activating the Wnt/β-catenin Pathway.

Article References:

Xu, Y., Wang, X., Tang, L. et al. FABP7 Enhances Endometrial Cancer Cell Migration and Stemness by Activating the Wnt/β-catenin Pathway.
Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11302-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10528-025-11302-0

Keywords: FABP7, endometrial cancer, Wnt/β-catenin pathway, cancer cell migration, cancer stemness.